Risk factors associated with degenerative aortic valve stenosis development and treatment
Degenerative aortic valve stenosis is the most common heart valve disease without established medical therapy to halt disease progression. The only available treatment involves aortic valve replacement by transcatheter aortic valve replacement (TAVR). The somatic mutations associated with the expansion of clonal haematopoiesis (CH) are linked to a poor prognosis for patients with stenosis undergoing TAVR. The EU-funded CHIP-AVS project will address the risk factors associated with the development and treatment of aortic valve stenosis. The study will focus on mutations in CH-driver genes that affect the processes leading to stenosis, the type of mutations involved in mediating the poor prognosis, and the impact of CH on the reversibility of cardiac fibrosis after the TAVR.
Fields of science
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Call for proposalSee other projects for this call
Funding SchemeERC - Support for frontier research (ERC)
60323 Frankfurt Am Main
See on map